10 biotechs to look out for in 2025
This issue of our newsletter is supported by Inpart.
As we near the end of this year, most biotech companies will be setting out their plans for 2025, as they continue to work towards bringing their innovative therapies through the clinic and to the market in an attempt to bring new and groundbreaking medicines to patients suffering from debilitating diseases.
You might remember that last year we documented nine biotechs we thought you should watch in 2024. Now, as the year has flown by, we’re ready to take a look at 10 companies that could have a significant impact on the biotech industry in 2025 – including the likes of RNA editing pioneer Wave Life Sciences, and the fastest-growing company of the year TG Therapeutics!
To find out more, read the full article: “10 biotech companies to watch in 2025”
A MESSAGE FROM OUR SPONSOR INPART
Partnering 2030: Biopharma report
Download Inpart’s latest report to hear from biotechs and out-licensors, following this year’s Partnering 2030 survey. The report includes real-world partnering experiences, challenges, and insights into working with top pharmaceutical firms.
Want to advertise with us? Become our next sponsor.
?? More noteworthy articles from this week:
Glycobiology is now emerging as an area that could potentially lead to a new type of cancer immunotherapy and become an alternative approach to using conventional immune checkpoint inhibitors, a type of drug that continues to face numerous challenges. In this article, we take a look at what glycobiology is, how it can be applied to cancer immunotherapy, and which companies are currently operating in the up-and-coming field of glyco-immunology.?
The penultimate month of the year saw a lot of biopharmas scouting for fellow biopharmas to advance therapies across different stages through to commercialization. Mergers and acquisitions worth billions were part of this wintry time. Moreover, biotech deals in antibody-drug conjugates, small molecules, antibody therapies, GLP-1 agonists, and precision medicine stood out in November 2024.
Clarivate recently released a report – “A decade of innovation in China” – offering a comprehensive analysis of how the country’s biotech landscape has evolved over the past 10 years, driven by targeted policies and an increasingly global outlook. As China has emerged as a powerhouse in the global biopharma ecosystem, we take a look at what the country has been up to in the last 10 years and how big it will be in the future of the industry.
Cancer vaccines are a kind of immunotherapy that are meant to recognize cancer cells in the body and destroy them. But what if they could prevent the spread of cancer altogether? Well, that’s precisely what OvarianVax, the world’s first ovarian cancer prevention vaccine, strives to do. And, while this is a significant milestone, other vaccine candidates to treat ovarian cancer are making progress across the globe too.?
There is a constant risk of severe, potentially life-threatening allergic reactions for individuals with peanut allergies, which leads to significant physical, social, and emotional burdens. IgGenix, a clinical-stage immunology biotechnology company, recently announced the first patient dosed in its phase 1 trial evaluating IGNX001, a novel monoclonal antibody-based therapeutic, for peanut allergy. Our guest on the podcast this week is Jessica Grossman, chief executive officer of IgGenix.
Adeno-associated viruses (AAVs) are promising delivery tools for gene therapy and are used in many clinical studies. However, less than ten AAV-based therapies have been approved to date. To mitigate the risk of serious side effects and even death, a comprehensive quality control and characterization process is crucial. This process includes identifying features that may influence efficacy and safety but are not yet fully understood.
??Enjoying these articles??Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.